» Authors » Jaap Kwekkeboom

Jaap Kwekkeboom

Explore the profile of Jaap Kwekkeboom including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 120
Citations 2989
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mammadov R, Selten J, Roest H, Verhoeven C, Maroni L, Bril S, et al.
Transplantation . 2023 Mar; 107(8):1764-1775. PMID: 36978227
Background: Primary sclerosing cholangitis (PSC) is a chronic progressive pathological process, related to inflammatory bowel disease and subsequent bacterial translocation. Liver transplantation (LT) is the only curative therapy, but outcomes...
2.
Noordam L, de Beijer M, Mancham S, Vogler I, Boor P, de Ruiter V, et al.
Oncoimmunology . 2022 Oct; 11(1):2131096. PMID: 36211805
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide due to high recurrence rates after curative treatment and being frequently diagnosed at an advanced stage. Immune-checkpoint inhibition...
3.
Rakke Y, Campos Carrascosa L, van Beek A, de Ruiter V, van Gemerden R, Doukas M, et al.
Cell Mol Gastroenterol Hepatol . 2022 Sep; 15(1):77-97. PMID: 36155259
Background & Aims: In contrast to mismatch repair deficient colorectal carcinoma (CRC), MMR proficient (pMMR) CRC does not respond to immune checkpoint blockade. We studied immune checkpoint stimulation via glucocorticoid-induced...
4.
Duizendstra A, de Knegt R, Nagtzaam N, Betjes M, Dik W, Litjens N, et al.
Transplant Proc . 2022 Sep; 54(7):1874-1880. PMID: 36100485
Background: Operationally tolerant liver transplant (LTx)-recipients can be weaned off immunosuppressive (IS) drugs without development of graft rejection. However, it is feared that liver fibrosis might develop after complete IS...
5.
Zhou G, Lieshout R, van Tienderen G, de Ruiter V, van Royen M, Boor P, et al.
Br J Cancer . 2022 May; 127(4):649-660. PMID: 35597867
Background: Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI will be effective for individual patients. Therefore,...
6.
Duizendstra A, van der Grift M, Boor P, Noordam L, de Knegt R, Peppelenbosch M, et al.
Front Immunol . 2022 Jan; 12:738837. PMID: 35087511
Spontaneous operational tolerance to the allograft develops in a proportion of liver transplant (LTx) recipients weaned off immunosuppressive drugs (IS). Several previous studies have investigated whether peripheral blood gene expression...
7.
Zhou G, Boor P, Bruno M, Sprengers D, Kwekkeboom J
Br J Cancer . 2021 Aug; 126(1):10-23. PMID: 34400801
Liver cancer is one of the most prevalent cancers, and the third most common cause of cancer-related mortality worldwide. The therapeutic options for the main types of primary liver cancer-hepatocellular...
8.
Xu Y, Campos Carrascosa L, Yeung Y, Chu M, Yang W, Djuretic I, et al.
Cancer Immunol Res . 2021 Aug; 9(10):1141-1157. PMID: 34376502
The use of cytokines for immunotherapy shows clinical efficacy but is frequently accompanied by severe adverse events caused by excessive and systemic immune activation. Here, we set out to address...
9.
Ge Z, Peppelenbosch M, Sprengers D, Kwekkeboom J
Front Immunol . 2021 Aug; 12:699895. PMID: 34367161
T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently...
10.
Duizendstra A, de Knegt R, Mancham S, Klepper M, Roelen D, Brand-Schaaf S, et al.
Liver Transpl . 2021 Jun; 28(1):98-112. PMID: 34081828
Spontaneous operational tolerance to the allograft develops in a proportion of liver transplantation (LT) recipients weaned off immunosuppressive (IS) drugs. Several studies have investigated whether peripheral blood circulating T cells...